Aarkstore.com - Pharmaceutical Outsourcing Opportunities Post-Launch: Contract Manufacturing and Contract Sales and Marketing, 3rd Edition
09/29/2009

This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing.

Online PR News – 29-September-2009 – – This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector.

A major factor driving the upward trend in the number of manufacturing projects being outsourced is that specialized production, i.e., sterile manufacturing, biopharmaceutical manufacturing and specialized processes, such as chiral chemistry and improvements in catalyst activity, is often not included in the core competency of pharmaceutical and biotechnology drug makers.

Detail on Biopharmaceutical Markets

The growing number of biotechnology-driven protein and peptide drugs, antibiotics, chemotherapeutic agents and other compounds administered as sterile injectables, with its concomitant technological requirements, has brought about an increase in the demand for contract sterile manufacturing services. The sheer numbers of biologics in the pipeline are driving drug makers to outsource specialized production rather than build new plants.

As part of its unique coverage of the outsourcing markets for manufacturing and sales, this report includes

* CMO and CSO Market Size and Forecasts
* Regional Market Breakout (US, Europe, Japan, Latin America, Rest of World)
* Overview of CMO/CSO Market and Key Drivers
* Key Issues and Trends
* Biopharmaceutical Manufacturing
* Assessment of Key Companies in the Market

Traditionally, large pharmaceutical companies considered sales and marketing a core competency, and built in-house sales teams and the infrastructure to support promotional activities, launches and general portfolio expansion. However, in recent years, consistent with the "lean-and-mean" business model evolving in the pharmaceutical industry, sales and marketing is shifting—albeit slowly—from a core competency to a prime candidate for outsourcing.

Primary and Secondary Research

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

For more information, please visit :
http://www.aarkstore.com/reports/Pharmaceutical-Outsourcing-Opportunities-Post-Launch-Contract-Manufacturing-and-Contract-Sales-and-Marketing-3rd-Edition-12946.html
Or email us at press@aarkstore.com or call +919272852585

visit our website